Endostar not checked
Jiangsu Simcere Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment”In the company’s words, NCT04914598 on ClinicalTrials.gov
- Tested for
- Malignant Pleural Effusion
- Main trialPhase 3
- “Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or ascites.”In the company’s words, NCT04914598 on ClinicalTrials.gov
- Other names
- recombinant human endostatin injection
Other drugs for Malignant Pleural Effusion
- JMKX000197Jemincare · Phase 2
- M701Wuhan YZY Biopharma Co., Ltd. · Phase 1/2
- WSK-IM02WestVac Biopharma Co., Ltd. · Phase 1
- MT027Suzhou Maximum Bio-tech Co., Ltd. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 10 Feb 2025 | A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions | |
| Phase 1Unknown | 25 Dec 2021 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026